Wall Street questions Achillion HCV pipeline viability after sovaprevir setback
This article was originally published in Scrip
Executive Summary
As if the FDA's decision to maintain the clinical hold on Achillion's Phase I study of its investigational hepatitis C virus (HCV) medicine sovaprevir was not bad enough for the company – triggering a 60% sell off of its shares on 30 September – Wall Street analysts picked apart the company's interim results of an ongoing Phase IIa trial of the drug in combination with another of the firm's experimental HCV treatments, ACH-3102.